Overview
NICE is unable to make a recommendation on iptacopan (Fabhalta) for treating complement 3 glomerulopathy in adults. This is because the company has withdrawn from the appraisal.
Last reviewed: 29 October 2025
Next review: We will review this decision if the company decides to restart the appraisal.